fluoxetine has been researched along with Brain Injuries in 22 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Brain Injuries: Acute and chronic (see also BRAIN INJURIES, CHRONIC) injuries to the brain, including the cerebral hemispheres, CEREBELLUM, and BRAIN STEM. Clinical manifestations depend on the nature of injury. Diffuse trauma to the brain is frequently associated with DIFFUSE AXONAL INJURY or COMA, POST-TRAUMATIC. Localized injuries may be associated with NEUROBEHAVIORAL MANIFESTATIONS; HEMIPARESIS, or other focal neurologic deficits.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fluoxetine administration attenuated BBB disruption, brain edema, and improved neurological function after SAH." | 7.88 | Fluoxetine attenuates neuroinflammation in early brain injury after subarachnoid hemorrhage: a possible role for the regulation of TLR4/MyD88/NF-κB signaling pathway. ( Cai, J; Chen, G; Chen, JS; Guan, GP; Li, JR; Liu, FY; Pan, HZ; Qian, C; Ruan, W; Wang, C; Wang, L, 2018) |
| "Fluoxetine is a well-studied serotonin selective reuptake inhibitor (SSRI)." | 5.72 | Fluoxetine attenuates apoptosis in early brain injury after subarachnoid hemorrhage through Notch1/ASK1/p38 MAPK signaling pathway. ( Li, C; Liu, M; Su, W; Zhong, W, 2022) |
| "Fluoxetine (FLX) is an anti-depressant of the selective serotonin reuptake inhibitors (SSRI) and was previously shown to be neuroprotective in vitro and in vivo." | 5.42 | The antidepressant fluoxetine protects the hippocampus from brain damage in experimental pneumococcal meningitis. ( Grandgirard, D; Leib, SL; Liechti, FD, 2015) |
| "Fluoxetine administration attenuated BBB disruption, brain edema, and improved neurological function after SAH." | 3.88 | Fluoxetine attenuates neuroinflammation in early brain injury after subarachnoid hemorrhage: a possible role for the regulation of TLR4/MyD88/NF-κB signaling pathway. ( Cai, J; Chen, G; Chen, JS; Guan, GP; Li, JR; Liu, FY; Pan, HZ; Qian, C; Ruan, W; Wang, C; Wang, L, 2018) |
| "Fluoxetine is a well-studied serotonin selective reuptake inhibitor (SSRI)." | 1.72 | Fluoxetine attenuates apoptosis in early brain injury after subarachnoid hemorrhage through Notch1/ASK1/p38 MAPK signaling pathway. ( Li, C; Liu, M; Su, W; Zhong, W, 2022) |
| "Traumatic brain injury was associated with an increase in intestinal permeability to FITC-dextran, increased lung vascular permeability, and worse performance on the rota-rod." | 1.72 | Fluoxetine reduces organ injury and improves motor function after traumatic brain injury in mice. ( Costantini, TW; Eliceiri, B; Weaver, JL, 2022) |
| "Fluoxetine (Fx) is an FDA-approved anti-depressant agent and one of the selective serotonin reuptake inhibitor drugs (SSRI), used in neurological disorder treatment." | 1.62 | Modulation of the Nitric Oxide/BH4 Pathway Protects Against Irradiation-Induced Neuronal Damage. ( Abdel-Rafei, MK; Moustafa, EM; Rashed, ER; Thabet, NM, 2021) |
| "Fluoxetine was administered via intravenous route 6 h after SAH." | 1.46 | Fluoxetine-enhanced autophagy ameliorates early brain injury via inhibition of NLRP3 inflammasome activation following subrachnoid hemorrhage in rats. ( Chen, G; Chen, JS; Chen, JY; Fan, LF; Gu, C; Li, JR; Nie, S; Peng, YC; Wang, C; Wang, L; Wang, ZJ; Wu, C; Xu, HZ; Yan, F, 2017) |
| "Thus, reactive gliosis and a significant increase in the expression of caspase-9 were found in the aforementioned brain area." | 1.46 | Subacute Fluoxetine Reduces Signs of Hippocampal Damage Induced by a Single Convulsant Dose of 4-Aminopyridine in Rats. ( de la Rosa, RF; Delgado, M; García-García, L; Pozo, MA; Shiha, AA, 2017) |
| "Fluoxetine (FLX) is an anti-depressant of the selective serotonin reuptake inhibitors (SSRI) and was previously shown to be neuroprotective in vitro and in vivo." | 1.42 | The antidepressant fluoxetine protects the hippocampus from brain damage in experimental pneumococcal meningitis. ( Grandgirard, D; Leib, SL; Liechti, FD, 2015) |
| "Fluoxetine treatment did not affect these behavioral alterations, but it did increase the social dominance of the injured mice, as assessed by the tube test." | 1.42 | The effects of chronic fluoxetine treatment following injury of medial frontal cortex in mice. ( Barneto, AA; Dyck, RH; McAllister, BB; Patel, PP; Spanswick, SC, 2015) |
| " Thus while fluoxetine enhanced neuroplasticity in the hippocampus after TBI, its chronic administration did not restore locomotor function or ameliorate memory deficits." | 1.37 | Fluoxetine increases hippocampal neurogenesis and induces epigenetic factors but does not improve functional recovery after traumatic brain injury. ( Hansen, K; Hong, SM; Kim, S; Liu, J; Neumann, M; Noble-Haeusslein, LJ; Wang, Y, 2011) |
| "Fluoxetine or vehicle was administered chronically on postinjury days 1-15." | 1.31 | Effects of fluoxetine on the 5-HT1A receptor and recovery of cognitive function after traumatic brain injury in rats. ( Hamm, RJ; Wilson, MS, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (22.73) | 18.2507 |
| 2000's | 5 (22.73) | 29.6817 |
| 2010's | 9 (40.91) | 24.3611 |
| 2020's | 3 (13.64) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, M | 1 |
| Zhong, W | 1 |
| Li, C | 1 |
| Su, W | 1 |
| Weaver, JL | 1 |
| Eliceiri, B | 1 |
| Costantini, TW | 1 |
| Thabet, NM | 1 |
| Rashed, ER | 1 |
| Abdel-Rafei, MK | 1 |
| Moustafa, EM | 1 |
| Li, JR | 2 |
| Xu, HZ | 1 |
| Nie, S | 1 |
| Peng, YC | 1 |
| Fan, LF | 1 |
| Wang, ZJ | 1 |
| Wu, C | 1 |
| Yan, F | 1 |
| Chen, JY | 1 |
| Gu, C | 1 |
| Wang, C | 2 |
| Chen, JS | 2 |
| Wang, L | 2 |
| Chen, G | 2 |
| Liu, FY | 1 |
| Cai, J | 1 |
| Ruan, W | 1 |
| Guan, GP | 1 |
| Pan, HZ | 1 |
| Qian, C | 1 |
| Liechti, FD | 1 |
| Grandgirard, D | 1 |
| Leib, SL | 1 |
| McAllister, BB | 1 |
| Spanswick, SC | 1 |
| Patel, PP | 1 |
| Barneto, AA | 1 |
| Dyck, RH | 1 |
| Shiha, AA | 1 |
| de la Rosa, RF | 1 |
| Delgado, M | 1 |
| Pozo, MA | 1 |
| García-García, L | 1 |
| Wang, Y | 1 |
| Neumann, M | 1 |
| Hansen, K | 1 |
| Hong, SM | 1 |
| Kim, S | 1 |
| Noble-Haeusslein, LJ | 1 |
| Liu, J | 1 |
| Hu, X | 1 |
| Li, Y | 1 |
| Hu, Z | 1 |
| Rudd, JA | 1 |
| Ling, S | 1 |
| Jiang, F | 1 |
| Davies, H | 1 |
| Fang, M | 1 |
| Vizi, ES | 1 |
| Kisfali, M | 1 |
| Lőrincz, T | 1 |
| Kuo, JR | 1 |
| Cheng, YH | 1 |
| Chen, YS | 1 |
| Chio, CC | 1 |
| Gean, PW | 1 |
| Horsfield, SA | 1 |
| Rosse, RB | 1 |
| Tomasino, V | 1 |
| Schwartz, BL | 1 |
| Mastropaolo, J | 1 |
| Deutsch, SI | 1 |
| Boyeson, MG | 1 |
| Harmon, RL | 1 |
| Jones, JL | 1 |
| Connor, DF | 1 |
| Steingard, RJ | 1 |
| Patterson, DE | 1 |
| Braverman, SE | 1 |
| Belandres, PV | 1 |
| Nahas, Z | 1 |
| Arlinghaus, KA | 1 |
| Kotrla, KJ | 1 |
| Clearman, RR | 1 |
| George, MS | 1 |
| Spinella, M | 1 |
| Eaton, LA | 1 |
| Wilson, MS | 1 |
| Hamm, RJ | 1 |
| Stengler-Wenzke, K | 1 |
| Müller, U | 1 |
| Zafonte, RD | 1 |
| Cullen, N | 1 |
| Lexell, J | 1 |
| Wroblewski, BA | 1 |
| Guidos, A | 1 |
| Leary, J | 1 |
| Joseph, AB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical Professor[NCT05138887] | Phase 2 | 366 participants (Anticipated) | Interventional | 2022-03-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for fluoxetine and Brain Injuries
| Article | Year |
|---|---|
Role of nonsynaptic GluN2B-containing NMDA receptors in excitotoxicity: evidence that fluoxetine selectively inhibits these receptors and may have neuroprotective effects.
Topics: Animals; Brain Injuries; Calcium; Fluoxetine; Humans; Models, Biological; Neuroprotective Agents; Re | 2013 |
A clinical approach to the pharmacotherapy of aggression in children and adolescents.
Topics: Adolescent; Aggression; Brain Injuries; Child; Child Behavior Disorders; Fluoxetine; Humans; Intelle | 1996 |
Serotonin agents in the treatment of acquired brain injury.
Topics: Brain Injuries; Citalopram; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Adminis | 2002 |
19 other studies available for fluoxetine and Brain Injuries
| Article | Year |
|---|---|
Fluoxetine attenuates apoptosis in early brain injury after subarachnoid hemorrhage through Notch1/ASK1/p38 MAPK signaling pathway.
Topics: Animals; Apoptosis; Brain Injuries; Fluoxetine; Mice; Mice, Inbred C57BL; Neuroprotective Agents; p3 | 2022 |
Fluoxetine reduces organ injury and improves motor function after traumatic brain injury in mice.
Topics: Animals; Brain Injuries; Brain Injuries, Traumatic; Disease Models, Animal; Fluoxetine; Humans; Infl | 2022 |
Modulation of the Nitric Oxide/BH4 Pathway Protects Against Irradiation-Induced Neuronal Damage.
Topics: Animals; Antidepressive Agents, Second-Generation; Apoptosis; Biopterins; Brain; Brain Injuries; Cra | 2021 |
Fluoxetine-enhanced autophagy ameliorates early brain injury via inhibition of NLRP3 inflammasome activation following subrachnoid hemorrhage in rats.
Topics: Animals; Anti-Inflammatory Agents; Autophagy; Brain Injuries; Fluoxetine; Inflammasomes; Male; NLR F | 2017 |
Fluoxetine attenuates neuroinflammation in early brain injury after subarachnoid hemorrhage: a possible role for the regulation of TLR4/MyD88/NF-κB signaling pathway.
Topics: Animals; Blood-Brain Barrier; Brain Edema; Brain Injuries; Calcium-Binding Proteins; Cytokines; Dise | 2018 |
The antidepressant fluoxetine protects the hippocampus from brain damage in experimental pneumococcal meningitis.
Topics: Animals; Animals, Newborn; Anti-Bacterial Agents; Antidepressive Agents, Second-Generation; Apoptosi | 2015 |
The effects of chronic fluoxetine treatment following injury of medial frontal cortex in mice.
Topics: Animals; Anxiety; Behavior, Animal; Brain Injuries; Disease Models, Animal; Fluoxetine; Male; Mice; | 2015 |
Subacute Fluoxetine Reduces Signs of Hippocampal Damage Induced by a Single Convulsant Dose of 4-Aminopyridine in Rats.
Topics: 4-Aminopyridine; Animals; Brain Injuries; Caspase 9; Cell Death; Convulsants; Disease Models, Animal | 2017 |
Fluoxetine increases hippocampal neurogenesis and induces epigenetic factors but does not improve functional recovery after traumatic brain injury.
Topics: Animals; Brain Injuries; Epigenesis, Genetic; Fluoxetine; Hippocampus; Male; Mice; Mice, Inbred C57B | 2011 |
The alteration of 5-HT(2A) and 5-HT(2C) receptors is involved in neuronal apoptosis of goldfish cerebellum following traumatic experience.
Topics: Analysis of Variance; Animal Fins; Animals; Antidepressive Agents, Tricyclic; Apoptosis; bcl-Associa | 2012 |
Involvement of extracellular signal regulated kinases in traumatic brain injury-induced depression in rodents.
Topics: Animals; Anxiety; Blotting, Western; Brain Injuries; Coloring Agents; Depression; Extracellular Sign | 2013 |
Fluoxetine's effects on cognitive performance in patients with traumatic brain injury.
Topics: Aged; Brain Injuries; Cognition Disorders; Fluoxetine; Humans; Male; Middle Aged; Pilot Projects; Se | 2002 |
Comparative effects of fluoxetine, amitriptyline and serotonin on functional motor recovery after sensorimotor cortex injury.
Topics: Amitriptyline; Brain Injuries; Fluoxetine; Motor Cortex; Psychomotor Performance; Serotonin; Time Fa | 1994 |
Speech dysfunction due to trazodone--fluoxetine combination in traumatic brain injury.
Topics: Adult; Brain Injuries; Depressive Disorder; Dysarthria; Fluoxetine; Humans; Male; Selective Serotoni | 1997 |
Rapid response of emotional incontinence to selective serotonin reuptake inhibitors.
Topics: Adult; Affective Symptoms; Aged; Brain Injuries; Cerebrovascular Disorders; Crying; Fluoxetine; Huma | 1998 |
Hypomania induced by herbal and pharmaceutical psychotropic medicines following mild traumatic brain injury.
Topics: Adult; Anti-Anxiety Agents; Bipolar Disorder; Brain Injuries; Buspirone; Depression; Drug Interactio | 2002 |
Effects of fluoxetine on the 5-HT1A receptor and recovery of cognitive function after traumatic brain injury in rats.
Topics: Animals; Brain Injuries; Cognition; Disease Models, Animal; Fluoxetine; Male; Maze Learning; Postura | 2002 |
Fluoxetine for OCD after brain injury.
Topics: Adolescent; Brain Injuries; Fluoxetine; Humans; Male; Obsessive-Compulsive Disorder; Selective Serot | 2002 |
Control of depression with fluoxetine and antiseizure medication in a brain-injured patient.
Topics: Adult; Brain Injuries; Depressive Disorder; Drug Therapy, Combination; Fluoxetine; Humans; Male; Phe | 1992 |